[HTML][HTML] Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology
More information about a person's genetic makeup, drug response, multi-omics response,
and genomic response is now available leading to a gradual shift towards personalized …
and genomic response is now available leading to a gradual shift towards personalized …
Machine learning approaches to drug response prediction: challenges and recent progress
Cancer is a leading cause of death worldwide. Identifying the best treatment using
computational models to personalize drug response prediction holds great promise to …
computational models to personalize drug response prediction holds great promise to …
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Anticancer uses of non-oncology drugs have occasionally been found, but such discoveries
have been serendipitous. We sought to create a public resource containing the growth …
have been serendipitous. We sought to create a public resource containing the growth …
xCell: digitally portraying the tissue cellular heterogeneity landscape
Tissues are complex milieus consisting of numerous cell types. Several recent methods
have attempted to enumerate cell subsets from transcriptomes. However, the available …
have attempted to enumerate cell subsets from transcriptomes. However, the available …
Gene expression based inference of cancer drug sensitivity
Inter and intra-tumoral heterogeneity are major stumbling blocks in the treatment of cancer
and are responsible for imparting differential drug responses in cancer patients. Recently …
and are responsible for imparting differential drug responses in cancer patients. Recently …
Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids
Patient-derived tumor organoids (PDOs) are a highly promising preclinical model that
recapitulates the histology, gene expression, and drug response of the donor patient tumor …
recapitulates the histology, gene expression, and drug response of the donor patient tumor …
CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics
Abstract CellMiner Cross-Database (CellMinerCDB, discover. nci. nih. gov/cellminercdb)
allows integration and analysis of molecular and pharmacological data within and across …
allows integration and analysis of molecular and pharmacological data within and across …
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the
worst prognosis and few effective therapies. Here we identified MS023, an inhibitor of type I …
worst prognosis and few effective therapies. Here we identified MS023, an inhibitor of type I …
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the
development of resistance to chemotherapy affecting over 30% of patients. New …
development of resistance to chemotherapy affecting over 30% of patients. New …
A review of connectivity map and computational approaches in pharmacogenomics
Large-scale perturbation databases, such as Connectivity Map (CMap) or Library of
Integrated Network-based Cellular Signatures (LINCS), provide enormous opportunities for …
Integrated Network-based Cellular Signatures (LINCS), provide enormous opportunities for …